Signatera by Natera vs Oncotype DX

Side-by-side comparison of cancer screening tests.

← Back to Cancer Screening

Signatera by Natera

FDA approved (MRD)
Variable

Patient-specific

Oncotype DX

Guideline recommended
Variable

Breast recurrence risk

Test Performance

FeatureSignatera by NateraOncotype DX
PriceVariableVariable
Cancers DetectedPatient-specificBreast recurrence risk
SensitivityVaries by cancerN/A
Specificity>99.8%N/A
Sample TypeBlood drawTumor tissue
FDA StatusFDA approved (MRD)Guideline recommended